Analysis of OS by subgroup demonstrated prolonged survival with pembrolizumab–chemotherapy compared with placebo–chemotherapy in Japanese patients with ESCC, PD-L1 CPS ≥ 10, and ESCC PD-L1 CPS ≥ 10 (Fig. 1b–d). Here, CD274 is linked to esophageal squamous cell carcinoma.